Skip to Content

Notice

Manufacturer of Controlled Substances; Notice of Application

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 20, 2007, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

DrugSchedule
Cathinone (1235)I
Methcathinone (1237)I
N-Ethylamphetamine (1475)I
N,N-Dimethylamphetamine (1480)I
Aminorex (1585)I
4-Methylaminorex (cis isomer) (1590)I
Gamma Hydroxybutyric acid (2010)I
Methaqualone (2565)I
Alpha-Ethyltryptamine (7249)I
Lysergic acid diethylamide (7315)I
Marihuana (7360)I
Tetrahydrocannabinols (7370)I
Mescaline (7381)I
3,4,5-Trimethoxyamphetamine (7390)I
4-Bromo-2,5-dimethoxyamphetamine (7391)I
4-Bromo-2,5-dimethoxyphenethylamine (7392)I
4-Methyl-2,5-dimethoxyamphetamine (7395)I
2,5-Dimethoxyamphetamine (7396)I
2,5-Dimethoxy-4-ethylamphetamine (7399)I
3,4-Methylenedioxyamphetamine (7400)I
5-Methoxy-3,4-methylenedioxyamphetamine (7401)I
N-Hydroxy-3,4-methylendioxyamphetamine (7402)I
3,4-Methylendioxy-N-ethylamphetamine (7404)I
3,4-Methylenedioxymethamphetamine (7405)I
4-Methoxyamphetamine (7411)I
Alpha-methyltryptamine (7432)I
Bufotenine (7433)I
Diethyltryptamine (7434)I
Dimethyltryptamine (7435)I
Psilocybin (7437)I
Psilocyn (7438)I
Acetyldihydrocodeine (9051)I
Benzylmorphine (9052)I
Codeine-N-oxide (9053)I
Dihydromorphine (9145)I
Heroin (9200)I
Hydromorphinol (9301)I
Methyldihydromorphine (9304)I
Morphine-N-oxide (9307)I
Normorphine (9313)I
Pholcodine (9314)I
Acetylmethadol (9601)I
Allylprodine (9602)I
Alphacetylmethadol except levo-alphacetylmethadol (9603)I
Alphameprodine (9604)I
Alphamethadol (9605)I
Betacetylmethadol (9607)I
Betameprodine (9608)I
Betamethadol (9609)I
Betaprodine (9611)I
Hydroxypethidine (9627)I
Noracymethadol (9633)I
Norlevorphanol (9634)I
Normethadone (9635)I
Trimeperidine (9646)I
Phenomorphan (9647)I
Para-Fluorofentanyl (9812)I
3-Methylfentanyl (9813)I
Alpha-Methylfentanyl (9814)I
Acetyl-alpha-methylfentanyl (9815)I
Beta-hydroxyfentanyl (9830)I
Beta-hydroxy-3-methylfentanyl (9831)I
Alpha-Methylthiofentanyl (9832)I
3-Methylthiofentanyl (9833)I
Thiofentanyl (9835)I
Amphetamine (1100)II
Methamphetamine (1105)II
Phenmetrazine (1631)II
Methylphenidate (1724)II
Ambobarbital (2125)II
Pentobarbital (2270)II
Secobarbital (2315)II
Glutethimide (2550)II
Nabilone (7379)II
1-Phenylcyclohexylamine (7460)II
Phencyclidine (7471)II
Start Printed Page 49316
1-Piperidinocyclohexane carbonitrile (8603)II
Alphaprodine (9010)II
Cocaine (9041)II
Codeine (9050)II
Dihydrocodeine (9120)II
Oxycodone (9143)II
Hydromorphone (9150)II
Diphenoxylate (9170)II
Benzoylecgonine (9180)II
Ethylmorphine (9190)II
Hydrocodone (9193)II
Levomethorphan (9210)II
Levorphanol (9220)II
Isomethadone (9226)II
Meperidine (9230)II
Methadone (9250)II
Methadone intermediate (9254)II
Dextropropoxyphene, bulk (non-dosage forms) (9273)II
Morphine (9300)II
Thebaine (9333)II
Levo-alphacetylmethadol (9648)II
Oxymorphone (9652)II
Noroxymorphone (9668)II
Racemethorphan (9732)II
Alfentanil (9737)II
Sufentanil (9740)II
Fentanyl (9801)II

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537; or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 29, 2007.

Start Signature

Dated: August 16, 2007.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

End Signature End Preamble

[FR Doc. E7-16937 Filed 8-27-07; 8:45 am]

BILLING CODE 4410-09-P